Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics.

ABSTRACT: Cancer is the second most common cause of death in developed countries with approximately 14 million newly diagnosed individuals and over 6 million cancer-related deaths in 2012. Many cancers are discovered at a more advanced stage but better survival rates are correlated with earlier detection. Current clinically approved cancer biomarkers are most effective when applied to patients with widespread cancer. Single biomarkers with satisfactory sensitivity and specificity have not been identified for the most common cancers and some biomarkers are ineffective for the detection of early stage cancers. Thus, novel biomarkers with better diagnostic and prognostic performance are required. Aberrant protein glycosylation is well known hallmark of cancer and represents a promising source of potent

SUBMITTER: Kirwan A 

PROVIDER: S-EPMC4609776 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature